OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

OPKO Health, Inc.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics, Inc.

OPKO Health is a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets.

Metric
Company Name	OPKO Health, Inc.	Axsome Therapeutics, Inc.
Symbol	OPK	AXSM
MSH ID	COM:OPKO	COM:AXSOME
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Medical - Diagnostics & Research	Biotechnology
Country	US	US
Stage		Post-IPO Equity
Employee Count	3.93K	569
Website	opko.com	axsome.com
LinkedIn
Founders

Metric
Market Cap	920.03M	3.92B
Enterprise Value
Monthly Web Traffic		7.82K
Web Traffic Growth		-0.74
Valuation
Raised Capital		225M

Metric
Revenue	863.50M	270.60M
Revenue (LTM)
Revenue (NTM)
Gross Profit	232.09M	237.70M
EBITDA	-52.76M	-176.07M
Operating Income	-158.06M	-182.91M
Net Income	-188.86M	-239.24M
EPS	-0.25	-5.27
Diluted EPS	-0.25	-5.27
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.34	0.90
Operating Profit Margin	-0.18	-0.86
EBITDA Margin	-0.06	-0.65
Net Profit Margin	-0.22	-0.88
Return on Equity	-0.13	-1.12
Return on Assets	-0.09	-0.41
Return on Capital Employed	-0.09	-0.52

COM:OPKO

OPKO Health, Inc.

Last Close

1.56

22/11 21:00

Market Cap

920.03M

Beta: -

Volume Today

3.21M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-3.55	-20.81
P/B Ratio	0.51	16.01
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.64	16.65
EV Multiple	-3.58	-11.57

Metric
Days Sales Outstanding	49.44	128.09
Days Payables Outstanding	45.36	506.28
Days Inventory Outstanding	42.30	229.29
Operating Cycle	97.34	383.54
Cash Conversion Cycle	52.47	-229.81
Asset Turnover	0.43	0.53

Metric
Operating Cash Flow	-28.20M	-145.08M
Free Cash Flow	-44.47M	-145.66M
Cash Flow to Debt	-0.10	-0.81
Operating Cash Flow/Sales	-0.03	-0.54
Free Cash Flow Yield	-0.05	-0.03

Metric
Cash & Equivalents	95.88M	386.19M
Accounts Receivable	3.41M	-57.12M
Inventory	65.70M	15.13M
Goodwill	598.26M	12.04M
Debt to Capitalization	0.26	0.65
Debt to Assets	0.12	0.31
Current Ratio	1.78	4.46
Quick Ratio	1.62	3.46

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	0.24
R&D to Revenue	0.10	0.37
SG&A to Revenue		0.44